FrancophonIA/ELRC3.0 huggingface dataset:
English: One patient in the cabazitaxel group died from cardiac failure.
Croatian: Jedan je bolesnik u skupini koja je primala kabazitaksel umro od zatajenja srca.
English: This was confirmed by a dedicated comparative pharmacokinetic study in solid cancer patients with normal renal function (8 patients), moderate (8 patients) and severe (9 patients) renal impairment, who received several cycles of cabazitaxel in single IV infusion up to 25 mg/m2.
Croatian: To je potvrđeno u posebnoj usporednoj farmakokinetičkoj studiji kod bolesnika sa solidnim tumorom, s normalnom bubrežnom funkcijom (8 bolesnika) te umjerenim (8 bolesnika) i teškim (9 bolesnika) oštećenjem bubrežne funkcije, koji su primili nekoliko ciklusa kabazitaksela u jednoj intravenskoj infuziji do 25 mg/m2.
English: Cabazitaxel is minimally excreted via the kidney (2.3% of the dose).
Croatian: Kabazitaksel se minimalno izlučuje putem bubrega (2,3% doze).
English: Cases of interstitial pneumonia/pneumonitis and interstitial lung disease, sometimes fatal have been reported with an unknown frequency (cannot be estimated from the available data) (see section 4.4).
Croatian: Respiratorni poremećaji Prijavljeni su slučajevi intersticijske upale pluća/pneumonitisa i intersticijske bolesti pluća, ponekad smrtonosni, s nepoznatom učestalošću (ne može se procijeniti iz dostupnih podataka) (vidjeti dio 4.4).
English: Study EFC11785 demonstrated a better safety profile for the cabazitaxel 20 mg/m2 dose.
Croatian: EFC11785 ispitivanje pokazalo je bolji sigurnosni profil za 20 mg/m2 kabazitaksela.
English: • severe stomach pain or stomach pain that doesn't go away.
Croatian: • jaki bolovi u trbuhu ili bolovi u trbuhu koji ne prolaze.
English: Cabazitaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells.
Croatian: Kabazitaksel je antineoplastično sredstvo koje djeluje tako što razara mikrotubularne mreže u stanicama.
English: The incidence of grade ≥3 clinical neutropenia and febrile neutropenia adverse reactions were 21.3% and 7.5% respectively.
Croatian: Incidencija kliničke neutropenije i febrilne neutropenije stupnja ≥ 3 iznosila je 21,3% odnosno 7,5%.
English: Administration of cabazitaxel to patients with mild hepatic impairment should be undertaken with caution and close monitoring of safety.
Croatian: Primjena kabazitaksela u bolesnika s blagim oštećenjem jetrene funkcije treba se provoditi uz oprez i pažljivo praćenje sigurnosti.
English: 1 vial of 1.5 ml concentrate and 1 vial of 4.5 ml solvent.
Croatian: 1 bočica s 1,5 ml koncentrata i 1 bočica s 4,5 ml otapala.
English: In 3 patients with severe hepatic impairment (total bilirubin >3 ULN), a 39% decrease in clearance was observed when compared to patients with mild hepatic impairment, indicating some effect of severe hepatic impairment on cabazitaxel pharmacokinetics.
Croatian: Kod 3 bolesnika s teškim oštećenjem jetrene funkcije (ukupan bilirubin >3 GGN), primijećeno je smanjenje klirensa od 39% u usporedbi s bolesnicima s blagim oštećenjem jetrene funkcije, što upućuje na određeni učinak teškog oštećenja jetrene funkcije na farmakokinetiku kabazitaksela.
English: • swelling of the feet or legs
Croatian: • oticanje stopala ili nogu
English: Interstitial pneumonia/pneumonitis and interstitial lung disease have been reported and may be associated with fatal outcome (see section 4.8).
Croatian: Prijavljene su intersticijska upala pluća/pneumonitis i intersticijska bolest pluća i mogu biti povezane sa smrtonosnim ishodom (vidjeti dio 4.8).
English: sanofi-aventis groupe 54, rue La Boétie F - 75008 Paris France
Croatian: sanofi-aventis groupe 54, rue La Boétie F - 75008 Paris Francuska
English: Patients had to have neutrophils >1,500/mm3, platelets >100,000/mm3, haemoglobin >10 g/dl, creatinine <1.5 x ULN, total bilirubin <1 x ULN, AST and ALT <1.5 x ULN.
Croatian: Bolesnici su morali imati broj neutrofila > 1500/mm3, broj trombocita > 100 000/mm3, hemoglobin > 10 g/dl, kreatinin < 1,5 x GGN, ukupni bilirubin < 1 x GGN te AST i ALT < 1,5 x GGN.
English: Overall survival was significant longer with JEVTANA compared to mitoxantrone (15.1 months versus 12.7 respectively), with a 30% reduction in the risk of death compared to mitoxantrone (see table 3 and figure 1).
Croatian: Ukupno preživljenje bilo je značajno dulje u skupini koja je primala lijek JEVTANA u usporedbi sa skupinom koja je primala mitoksantron (15,1 mjesec u odnosu na 12,7 mjeseci), uz 30%-tno smanjenje rizika od smrti u usporedbi s mitoksantronom (vidjeti Tablicu 3. i Sliku 1.).
English: This resulting concentrate-solvent mixture contains 10 mg/ml of cabazitaxel (at least 6 ml deliverable volume).
Croatian: Tako pripremljena mješavina koncentrata i otapala sadrži 10 mg/ml kabazitaksela (najmanje 6 ml volumena koji se može primijeniti).
English: There is no relevant use of JEVTANA in the paediatric population.
Croatian: Ne postoji relevantna primjena lijeka JEVTANA u pedijatrijskoj populaciji.
English: The use of JEVTANA should be confined to units specialised in the administration of cytotoxics and it should only be administered under the supervision of a physician experienced in the use of anticancer chemotherapy.
Croatian: JEVTANA se smije primjenjivati samo na odjelima specijaliziranima za primjenu citotoksičnih lijekova i to isključivo pod nadzorom liječnika s iskustvom u primjeni antitumorske kemoterapije.
English: Therefore concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) should be avoided as an increase of plasma concentrations of cabazitaxel may occur (see sections 4.2 and 4.4).
Croatian: Stoga je potrebno izbjegavati istodobnu primjenu sa snažnim inhibitorima CYP3A (npr. ketokonazol, itrakonazol, klaritromicin, indinavir, nefazodon, nelfinavir, ritonavir, sakvinavir, telitromicin, vorikonazol), jer može doći do povećanja koncentracije kabazitaksela u plazmi (vidjeti dijelove 4.2 i
English: Renal failure including cases with fatal outcome has been observed.
Croatian: uključujući one sa smrtnim ishodom.
English: Based on safety and tolerability data, cabazitaxel dose should be reduced in patients with mild hepatic impairment (see sections 4.2, 4.4).
Croatian: Prema podacima o sigurnosti i podnošljivosti, doza kabazitaksela treba se smanjiti kod bolesnika s blagim oštećenjem jetrene funkcije (vidjeti dijelove 4.2, 4.4).
English: Talk to your doctor before getting vaccinations while you are receiving JEVTANA.
Croatian: Obratite se svom liječniku prije nego primite neko cjepivo dok se liječite lijekom JEVTANA.
English: Adverse reactions not observed in clinical studies, but seen in dogs after single dose, 5-day and weekly administation at exposure levels lower than clinical exposure levels and with possible relevance to clinical use were arteriolar/periarterolar necrosis in the liver, bile ductule hyperplasia and/or hepatocellular necrosis (see section 4.2).
Croatian: Nuspojave koje nisu zabilježene u kliničkim ispitivanjima, ali su zapažene u pasa nakon jednokratne doze, 5-dnevne i tjedne primjene pri razinama izloženosti nižima od kliničkih, te bi mogle biti značajne za kliničku primjenu, bile su arteriolarna/periarteriolarna nekroza jetre, hiperplazija žučnih kanalića i/ili hepatocelularna nekroza (vidjeti dio 4.2).
English: After initial dilution of JEVTANA 60 mg concentrate with the entire contents of the solvent vial chemical and physical in-use stability has been demonstrated for 1 hour at ambient temperature.
Croatian: Nakon početnog razrjeđenja JEVTANA 60 mg koncentrata s cjelokupnim sadržajem bočice s otapalom dokazana kemijska i fizikalna stabilnost lijeka u primjeni je 1 sat, uz čuvanje na sobnoj temperaturi.
English: Cabazitaxel treatment should be discontinued in case of any degradation of renal function to renal failure ≥CTCAE 4.0 Grade 3.
Croatian: Liječenje kabazitakselom potrebno je prekinuti u slučaju bilo kakvog pogoršanja bubrežne funkcije do zatajenja bubrega stupnja ≥ 3 prema CTCAE 4,0.
English: After 1-hour intravenous administration at 25 mg/m2 cabazitaxel in patients with metastatic prostate cancer (n=67), the Cmax was 226 ng/ml (Coefficient of Variation (CV): 107%) and was reached at the end of the 1-hour infusion (Tmax).
Croatian: Nakon jednosatne intravenske primjene kabazitaksela u dozi od 25 mg/m2 u bolesnika s metastatskim karcinomom prostate (n=67) Cmax je iznosio 226 ng/ml (koeficijent varijacije (CV): 107%), a dostignut je na kraju jednosatne infuzije (Tmax).
English: The infusion solution should be used immediately.
Croatian: Otopina za infuziju mora se primijeniti odmah.
English: • lack of white blood cells associated with fever and infection
Croatian: • infekcije mokraćnih puteva • smanjenje broja bijelih krvnih stanica udružen s vrućicom i infekcijom
English: As an example, a dose of 45 mg JEVTANA would require 4.5 ml of the concentrate-solvent mixture prepared following Step 1.
Croatian: Na primjer, za dozu lijeka JEVTANA od 45 mg potrebno je 4,5 ml mješavine koncentrata i otapala pripremljene kako je opisano u koraku 1.
English: One pack contains one vial of concentrate and one vial of solvent:
Croatian: Jedno pakiranje sadrži jednu bočicu s koncentratom i jednu bočicu s otapalom:
English: The following two-step dilution process must be carried out in an aseptic manner for preparing the solution for infusion.
Croatian: Sljedeći postupak razrjeđivanja za pripremu otopine za infuziju u dva koraka potrebno je provesti u aseptičkim uvjetima.
English: In vitro, cabazitaxel has also been shown to inhibit the transport proteins of the Organic Anion Transport Polypeptides OATP1B1.
Croatian: U uvjetima in vitro pokazalo se da kabazitaksel također inhibira transportne proteine polipeptida koji transportiraju organske anione - OATP1B1.
English: The phase 2 part did not demonstrate efficacy of cabazitaxel as single agent in paediatric population with recurrent or refractory diffuse intrinsic pontine glioma (DIPG) and high grade glioma (HGG) treated at 30 mg/m².
Croatian: Faza 2 ispitivanja nije pokazala djelotvornost kabazitaksela kao monoterapije u pedijatrijskoj populaciji sa rekurentnim ili refraktornim difuznim intrinzičnim gliomom ponsa i gliomom visokog stupnja malignosti liječenog s dozom od 30 mg/m2.
English: All Grade events among cardiac disorders were more common on cabazitaxel of which 6 patients (1.6%) had Grade ≥3 cardiac arrhythmias.
Croatian: Srčani poremećaji i aritmije Nuspojave svih stupnjeva koje se ubrajaju u srčane poremećaje bile su češće u bolesnika koji su primali kabazitaksel, od kojih je 6 bolesnika (1,6%) imalo srčanu aritmiju stupnja ≥ 3.
English: A population pharmacokinetic analysis carried out in 170 patients that included 14 patients with moderate renal impairment (creatinine clearance in the range of 30 to 50 ml/min) and 59 patients with mild renal impairment (creatinine clearance in the range of 50 to 80 ml/min) showed that mild to moderate renal impairment did not have meaningful effects on the pharmacokinetics of cabazitaxel.
Croatian: Populacijska farmakokinetička analiza provedena u 170 bolesnika, među kojima je bilo 14 bolesnika s umjerenim oštećenjem bubrežne funkcije (klirens kreatinina u rasponu od 30 do 50 ml/min) i 59 bolesnika s blagim oštećenjem bubrežne funkcije (klirens kreatinina u rasponu od 50 do 80 ml/min), pokazala je da blago do umjereno oštećenje bubrežne funkcije nema značajan učinak na farmakokinetiku kabazitaksela.
English: • Severe hepatic impairment (total bilirubin >3 x ULN).
Croatian: • Teško oštećenje jetrene funkcije (ukupan bilirubin >3 x GGN).
English: In the JEVTANA group, the mean age was 68 years, range (46-92) and the racial distribution was 83.9% Caucasian, 6.9% Asian/Oriental, 5.3% Black and 4% Others.
Croatian: U skupini koja je primala lijek JEVTANA prosječna je dob bila 68 godina (raspon od 46 do 92), a rasna distribucija sljedeća: 83,9% bijelci, 6,9% Azijati, 5,3% crnci i 4% ostali.
English: Anaemia has been observed in patients receiving cabazitaxel (see section 4.8).
Croatian: Anemija je zabilježena u bolesnika koji su primali kabazitaksel (vidjeti dio 4.8).
English: However, in repeated-dose toxicity studies, degeneration of seminal vesicle and seminiferous tubule atrophy in the testis were observed in rats, and testicular degeneration (minimal epithelial single cell necrosis in epididymis), was observed in dogs.
Croatian: Međutim, u ispitivanjima toksičnosti ponovljenih doza opažena je degeneracija seminalnih vezikula i atrofija sjemenovodnih kanalića u testisima štakora te degeneracija testisa (minimalna nekroza pojedinačnih epitelnih stanica u epididimisu) u pasa.
English: This study included patients over 18 years of age with metastatic castration resistant prostate cancer either measurable by RECIST criteria or non-measurable disease with rising PSA levels or appearance of new lesions, and Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
Croatian: U navedeno su ispitivanje bili uključeni bolesnici stariji od 18 godina s metastatskim karcinomom prostate rezistentnim na kastraciju mjerljivim prema RECIST kriterijima ili s nemjerljivom bolešću uz rastuće razine PSA ili pojavu novih lezija te s ECOG (engl.
English: For instructions on preparation and administration of the product, see section 6.6.
Croatian: Za uputu o pripremi i primjeni lijeka vidjeti dio 6.6.
English: Concomitant administration of aprepitant, a moderate CYP3A inhibitor, had no effect on cabazitaxel clearance.
Croatian: Istodobna primjena s aprepitantom, umjerenim inhibitorom CYP3A, nije utjecala na klirens kabazitaksela
English: Appropriate measures should be taken to identify the cause and intensively treat the patients if this occurs.
Croatian: Pojave li se ovakvi poremećaji, potrebno je poduzeti odgovarajuće mjere s ciljem utvrđivanja njihovog uzroka te intenzivno liječiti bolesnike.
English: JEVTANA + prednisone n=378
Croatian: JEVTANA + prednizon n=378
English: Marketing Authorisation Holder sanofi-aventis groupe 54, rue La Boétie F - 75008 Paris
Croatian: Nositelj odobrenja za stavljanje lijeka u promet sanofi-aventis groupe 54, rue La Boétie F - 75008 Paris Francuska
English: The recommended dose of JEVTANA is 25 mg/m2 administered as a 1 hour intravenous infusion every 3 weeks in combination with oral prednisone or prednisolone 10 mg administered daily throughout treatment.
Croatian: Preporučena doza lijeka JEVTANA iznosi 25 mg/m2, primijenjeno u obliku jednosatne intravenske infuzije svaka 3 tjedna, u kombinaciji s 10 mg prednizona ili prednizolona koji se uzimaju peroralno svaki dan tijekom liječenja.
English: Cabazitaxel had a high plasma clearance of 48.5 l/h (26.4 l/h/m² for a patient with a median BSA of 1.84 m²) and a long terminal half-life of 95 hours.
Croatian: Kabazitaksel ima visok klirens iz plazme od 48,5 l/h (26,4 l/h/m2 u bolesnika s medijanom tjelesne površine od 1,84 m2) te dug terminalni poluvijek od 95 sati.
English: CBZ20=Cabazitaxel 20 mg/m2, CBZ25=Cabazitaxel 25 mg/m2, PRED=Prednisone/Prednisolone a All grade adverse reactions with an incidence higher than 10% b Grade ≥ 3 adverse reactions with an incidence higher than 5% c Based on laboratory values
Croatian: CBZ20= 20 mg/m2 kabazitaksela, CBZ25= 25 mg/m2 kabazitaksela, PRED=prednizon/prednizolon a Nuspojave svih stupnjeva s incidencijom većom od 10% b Nuspojave stupnja ≥ 3 s incidencijom većom od 5%
English: You should not be given JEVTANA if any of the above apply to you.
Croatian: Ne smijete primati lijek JEVTANA ako se nešto od navedenog odnosi na Vas.
English: Neutropenia is the most common adverse reaction of cabazitaxel (see section 4.8).
Croatian: Neutropenija je najčešća nuspojava kabazitaksela (vidjeti dio 4.8).
English: OTHER This vial contains an overfill.
Croatian: Ova bočica sadrži dodatnu količinu punjenja.
English: Therefore, at therapeutic doses, co-administration of CYP3A substrates with cabazitaxel to patients is not expected to have any clinical impact.
Croatian: Stoga se ne očekuje da bi pri terapijskim dozama istodobna primjena supstrata CYP3A i kabazitaksela mogla u bolesnika izazvati neki klinički učinak.
English: Grade ≥ 3 neutropenia
Croatian: Neutropenija stupnja ≥ 3
English: None were considered related by the investigator.
Croatian: Prema mišljenju ispitivača, niti jedan slučaj nije bio povezan s primjenom lijeka.
English: Cardiac arrhythmias have been reported, most commonly tachycardia and atrial fibrillation (see section 4.8).
Croatian: Rizik od srčanih aritmija Prijavljeni su slučajevi srčanih aritmija, najčešće tahikardija i fibrilacija atrija (vidjeti dio 4.8).
English: Risk of nausea, vomiting, diarrhoea and dehydration If patients experience diarrhoea following administration of cabazitaxel they may be treated with commonly used anti-diarrhoeal medicinal products.
Croatian: Rizik od mučnine, povraćanja, proljeva i dehidracije Ako bolesnici nakon primjene kabazitaksela dobiju proljev, mogu se liječiti uobičajenim lijekovima protiv proljeva.
English: The study met its primary objective of demonstrating the non-inferiority of cabazitaxel 20 mg/m2 in comparison with 25 mg/m2 (see table 4).
Croatian: Ispitivanje je zadovoljilo svoj primarni cilj pokazujući neinferiornost kabazitaksela u dozi od 20 mg/m2 u usporedbi s dozom od 25 mg/m2 (vidjeti tablicu 4).
English: JEVTANA should only be prepared and administered by personnel trained in handling cytotoxic agents.
Croatian: Lijek JEVTANA smije pripremati i primjenjivati samo osoblje obučeno za rukovanje citotoksičnim tvarima.
English: A total of 755 patients were randomised to receive either JEVTANA 25 mg/m2 intravenously every 3 weeks for a maximum of 10 cycles with prednisone or prednisolone 10 mg orally daily (n=378), or to receive mitoxantrone 12 mg/m2 intravenously every 3 weeks for a maximum of 10 cycles with prednisone or prednisolone 10 mg orally daily (n=377).
Croatian: Ukupno je randomizirano 755 bolesnika koji su primali ili lijek JEVTANA u dozi od 25 mg/m2 intravenski svaka 3 tjedna do najviše 10 ciklusa, uz prednizon ili prednizolon u peroralnoj dozi od 10 mg na dan (n=378), ili mitoksantron 12 mg/m2 intravenski svaka 3 tjedna do najviše 10 ciklusa, uz prednizon ili prednizolon u peroralnoj dozi od 10 mg na dan (n=377).
English: Cabazitaxel inhibited the transport of P-glycoprotein (PgP) (digoxin, vinblastin), Breast-Cancer-Resistant-Proteins (BCRP) (methotrexate) and Organic Anion Transporting Polypeptide OATP1B3 (CCK8) at concentrations at least 15 fold what is observed in clinical setting while it inhibited the transport of OATP1B1 (estradiol-17β-glucuronide) at concentrations only 5 fold what is observed in clinical setting.
Croatian: Breast-Cancer-Resistant-Protein) (metotreksat) i polipeptida koji transportira organske anione OATP1B3 (CCK8), dok je je inhibirao transport OATP1B1 (estradiol-17β glukuronida) u koncentracijama samo 5 puta većima od onih zabilježenih u kliničkoj primjeni.
English: JEVTANA in combination with prednisone or prednisolone is indicated for the treatment of adult patients with metastatic castration resistant prostate cancer previously treated with a docetaxel-containing regimen (see section 5.1).
Croatian: JEVTANA je u kombinaciji s prednizonom ili prednizolonom indicirana za liječenje odraslih bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju, koji su prethodno liječeni kemoterapijskim protokolom koji je sadržavao docetaksel (vidjeti dio 5.1).
English: A statistically significantly higher risk of PSA progression in patients with the 20 mg/m2 dose with respect to the 25 mg/m2 dose was observed (HR 1.195 ; 95%CI: 1.025 to 1.393).
Croatian: Statistički značajno veći rizik od progresije PSA opažen je u bolesnika s dozom od 20 mg/m2 s obzirom na bolesnike s dozom od 25 mg/m2 (HR 1,195; 95% CI: 1,025 do
English: JEVTANA is contraindicated in patients with severe hepatic impairment (see section 4.3).
Croatian: JEVTANA je kontraindicirana u bolesnika s teškim oštećenjem jetrene funkcije (vidjeti dio 4.3).
English: JEVTANA should not be used during breast-feeding.
Croatian: JEVTANA se ne smije primjenjivati tijekom dojenja.
English: • uncomfortable feeling in the stomach, heart burn or belching
Croatian: • osjećaj nelagode u želucu, žgaravica ili podrigivanje
English: The concentrate is a clear yellow to brownish-yellow oily solution.
Croatian: Koncentrat je bistra žuta do smećkastožuta uljna otopina.
English: Renal colic Haematuria Pollakiuria Hydronephrosis Urinary retention Urinary incontinence Ureteric obstruction
Croatian: Često polakizurija hidronefroza retencija urina inkontinencija urina opstrukcija uretera
English: Repeated administration of rifampin (600 mg once daily), a strong CYP3A inducer, resulted in an increase in cabazitaxel clearance of 21% corresponding to a decrease in AUC of 17%.
Croatian: Induktori CYP3A Ponovljena primjena snažnog induktora CYP3A, rifampina, (600 mg jednom na dan) rezultirala je povećanjem klirensa kabazitaksela za 21%, što odgovara smanjenju AUC-a za 17%.
English: Other medicines and JEVTANA
Croatian: Drugi lijekovi i JEVTANA
English: The volume of distribution (Vss) was 4870 l (2640 l/m² for a patient with a median BSA of 1.84 m²) at steady state.
Croatian: Volumen distribucije u stanju dinamičke ravnoteže (Vss) iznosio je 4870 l (2610 l/m2 u bolesnika s medijanom tjelesne površine od 1,84 m2).
English: A hazard ratio < 1 indicates a lower risk of cabazitaxel 20 mg/m2 with respect to 25 mg/m2.
Croatian: Omjer hazarda <1 ukazuje na niži rizik kabazitaksela u dozi od 20 mg/m2 s obzirom na dozu od 25 mg/m2.
English: A sub-group of 59 patients received prior cumulative dose of docetaxel <225 mg/m² (29 patients in JEVTANA arm, 30 patients in mitoxantrone arm).
Croatian: Podskupina od 59 bolesnika prethodno je primila kumulativnu dozu docetaksela od < 225 mg/m2 (29 bolesnika u skupini koja je primala lijek JEVTANA i 30 bolesnika u skupini koja je primala mitoksantron).
English: Repeated administration of ketoconazole (400 mg once daily), a strong CYP3A inhibitor, resulted in a 20% decrease in cabazitaxel clearance corresponding to a 25% increase in AUC.
Croatian: Ponovljena primjena snažnog inhibitora CYP3A, ketokonazola, (400 mg jednom na dan) rezultirala je smanjenjem klirensa kabazitaksela za 20%, što odgovara povećanju AUC-a za 25%.
English: The incidence of the following grade ≥3 adverse reactions were higher in patients 65 years of age compared to younger patients; neutropenia based on laboratory abnormalities (86.3% versus 73.3%), clinical neutropenia (23.8% versus 16.8%) and febrile neutropenia (8.3% versus 6.1%) (see sections 4.2 and 4.4).
Croatian: Incidencija sljedećih nuspojava stupnja ≥ 3 bila je veća u bolesnika u dobi od ≥ 65 godina u usporedbi s mlađim bolesnicima: neutropenija na temelju laboratorijskih odstupanja (86,3% u odnosu na 73,3%), klinička neutropenija (23,8% u odnosu na 16,8%) i febrilna neutropenija (8,3% u odnosu na 6,1%); (vidjeti dijelove 4.2 i 4.4).
English: mitoxantrone + prednisone n=377
Croatian: mitoksantron + prednizon n=377
English: Cabazitaxel is eliminated primarily via liver metabolism.
Croatian: Oštećenje jetrene funkcije Kabazitaksel se primarno eliminira metabolizacijom u jetri.
English: The efficacy and safety of JEVTANA in combination with prednisone or prednisolone were evaluated in a randomised, open-label, international, multi-center, phase III study (EFC6193 study), in patients with metastatic castration resistant prostate cancer previsouly treated with a docetaxel containing regimen.
Croatian: Djelotvornost i sigurnost primjene lijeka JEVTANA u kombinaciji s prednizonom ili prednizolonom procijenjena je u randomiziranom, otvorenom, međunarodnom multicentričnom kliničkom ispitivanju faze III (EFC6193 ispitivanje) u bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju, koji su prethodno liječeni kemoterapijskim protokolom koji je uključivao docetaksel.
English: In addition, patients should also refrain from taking St. John's Wort.
Croatian: Osim toga, bolesnici ne bi smjeli uzimati gospinu travu.